Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416875 | 0.87 | ALDH1A1 (0.47) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 | |
| SCHEMBL6651615 | 0.87 | ALDH1A1 (0.39) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 | |
| SCHEMBL15535315 | 0.79 | ALDH1A1 (0.47) | ALDH1A1NPC1CYP2C9EPHX2SMN1; SMN2 | |
| SCHEMBL3292905 | 0.78 | ALDH1A1 (0.42) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 | |
| SCHEMBL31416858 | 0.78 | CYP19A1 (0.40) | ALDH1A1NPC1EPHX2SMN1; SMN2ITGB1 | |
| SCHEMBL23460047 | 0.76 | DPP4 (0.49) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 | |
| SCHEMBL3805389 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 | |
| SCHEMBL255570 | 0.76 | DPP4 (0.49) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 | |
| SCHEMBL1089252 | 0.76 | ALDH1A1 (0.50) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 | |
| SCHEMBL3805395 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPC1ALOX15SLC22A2SLC47A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306107-A1 | METAL HOMEOSTASIS RESTORATION AGENT | Oxford Antibiotic Group GmbH (AT) | 2024-01-17 | — | — | EP | claimed |
| US-20230312807-A1 | SPANDEX FIBER WITH REVERSIBLE TRIPLE-SHAPE MEMORY EFFECT AND PREPARATION METHOD THEREOF | WUYI UNIVERSITY (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022156149-A1 | SPANDEX FIBER HAVING REVERSIBLE THREE-SHAPE MEMORY EFFECT, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 五邑大学 | 2022-07-28 | — | — | WO | disclosed |
| CN-112663168-B | Spandex fiber with reversible shape memory effect and preparation method and application thereof | 五邑大学 | 2022-07-19 | — | — | CN | disclosed |
| CN-112962165-B | Spandex fiber with reversible three-shape memory effect and preparation method and application thereof | 五邑大学 | 2022-07-05 | — | — | CN | disclosed |
| CN-112962165-A | Spandex fiber with reversible three-shape memory effect and preparation method and application thereof | 五邑大学 | 2021-06-15 | — | — | CN | disclosed |
| CN-112663168-A | Spandex fiber with reversible shape memory effect and preparation method and application thereof | 五邑大学 | 2021-04-16 | — | — | CN | disclosed |
| CN-105802196-B | A kind of high molecular material and preparation method thereof with double process shape-memory effect | 中山大学 | 2018-08-07 | — | — | CN | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20060276439-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NITROMED, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-20050038029-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NITROMED, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| US-6790864-B2 | NONSTEROIDAL ANTIINFLAMMATORY DRUGS WHICH HAVE BEEN SUBSTITUTED WITH A NITROGEN MONOXIDE GROUP; COMPOSITIONS COMPRISING (I) A NONSTEROIDAL ANTIINFLAMMATORY DRUG, WHICH CAN OPTIONALLY BE SUBSTITUTED WITH A NITROGEN MONOXIDE GROUP | NITROMED, INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030109520-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NICOX S.A. (FR) | 2003-06-12 | — | — | US | disclosed |
| US-6482846-B1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NITROMED, INC. | 2002-11-19 | — | — | US | disclosed |
| US-6323234-B1 | TRANSFER OR RELEASE NITRIC OXIDE OR IS A SUBSTRATE FOR NITRIC OXIDE SYNTHASE WITH CARRIERS | NITROMED, INC. | 2001-11-27 | — | — | US | disclosed |
| US-6048858-A | HETERORING CONTAINING A SULFONAMIDE GROUP | NITROMED, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-6043233-A | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE, OR IS A SUBSTRATE FOR NITRIC OXIDE SYNTHASE. | NITROMED, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5703073-A | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NITROMED, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-4536594-A | Process for the preparation of beta-disubstituted monocarboxylic acids | ELF FRANCE (FR) | 1985-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038029-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NOS2, NOS3, MB | ALDH1A1 1342/4885NPC1 1750/4885ALOX15 82/4885 |
| US-20030109520-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NOS2, NOS3, MB | ALDH1A1 1342/4885NPC1 1750/4885ALOX15 82/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | ALDH1A1 2335/4885NPC1 4596/4885ALOX15 1960/4885 |
| US-20060276439-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NOS2, NOS3, MB | ALDH1A1 1342/4885NPC1 1750/4885ALOX15 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.